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The urotensinergic system plays central roles in the physiological regulation of major
mammalian organ systems, including the cardiovascular system. As a matter of fact, this
system has been linked to numerous pathophysiological states including atherosclerosis,
heart failure, hypertension, diabetes as well as psychological, and neurological disorders.
The delineation of the (patho)physiological roles of the urotensinergic system has been
hampered by the absence of potent and selective antagonists for the urotensin II-receptor
(UT). Thus, a more precise definition of the molecular functioning of the urotensinergic
system, in normal conditions as well as in a pathological state is still critically needed.
The recent discovery of nuclear UT within cardiomyocytes has highlighted the cellular
complexity of this system and suggested that UT-associated biological responses are
not only initiated at the cell surface but may result from the integration of extracellular
and intracellular signaling pathways. Thus, such nuclear-localized receptors, regulating
distinct signaling pathways, may represent new therapeutic targets. With the recent
observation that urotensin II (UII) and urotensin II-related peptide (URP) exert different
biological effects and the postulate that they could also have distinct pathophysiological
roles in hypertension, it appears crucial to reassess the recognition process involving
UII and URP with UT, and to push forward the development of new analogs of the UT
system aimed at discriminating UII- and URP-mediated biological activities. The recent
development of such compounds, i.e. urocontrin A and rUII(1–7), is certainly useful to
decipher the specific roles of UII and URP in vitro and in vivo. Altogether, these studies,
which provide important information regarding the pharmacology of the urotensinergic
system and the conformational requirements for binding and activation, will ultimately
lead to the development of potent and selective drugs.
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THE UROTENSINERGIC SYSTEM
During the last decade, the urotensinergic system has drawn
the attention of the scientific community due to its marked
involvement in various pathological states including cardiovas-
cular diseases. Initially isolated from the caudal neurosecretory
system of the teleostean fish Gillichthys mirabilis, urotensin II
(UII), a somatostatin-like peptide, was first characterized as a
spasmogenic agent (Pearson et al., 1980). During more than 15
years, this peptide and its unknown receptors were thought to
be restricted to fishes until it was demonstrated that UII was
able to induce the relaxation of the mouse anococcygeus mus-
cle (Gibson et al., 1984) and provoke the contraction of rat aortic
strips (Gibson, 1987). These results, suggesting the presence of an
homologous peptide in higher vertebrates, led to the isolation and
characterization of UII in the frog Rana ridibunda (Conlon et al.,
1992). Following this discovery, UII isoforms were either charac-
terized or isolated in various vertebrate species including humans
(Vaudry et al., 2010). A few years later, a peptide paralog, termed
urotensin II-related peptide (URP), was isolated in rat brain
extracts and subsequently identified in other mammalian species
(Vaudry et al., 2010). Sequence comparison of all UII and URP
isoforms revealed a striking conservation of the C-terminal cyclic
hexapeptide (Vaudry et al., 2010). Conversely, the N-terminal
region is highly variable both in length, ranging from 11 residues
in humans to 17 residues in mice, and sequence composition
(Figure 1) (Vaudry et al., 2010). In the human genome, UII and
URP genes are respectively found at position 1p36 and 3q29 (Sugo
et al., 2003). Those two genes are primarily expressed inmotoneu-
rons located in discrete brainstem nuclei and in the ventral horn
of the spinal cord (Vaudry et al., 2010). However, UII and URP
mRNAs have also been detected, although at a much lower level,
in various peripheral tissues including the pituitary, heart, spleen,
lung, liver, thymus, pancreas, kidney, small intestine, adrenal, and
prostate (Figure 2) (Vaudry et al., 2010).
Both peptides are endogenous ligands of a G protein-coupled
receptor initially identified as the orphan GPR14 receptor (Ames
et al., 1999; Liu et al., 1999; Mori et al., 1999; Nothacker et al.,
1999). Structural studies of this urotensin II receptor (UT)
showed that, in addition to the common features found in the 1A
GPCR family, such as the existence of a disulfide bridge between
extracellular loops 1 and 2, N-linked glycosylation sites in the
N-terminus portion, and phosphorylation sites in intracellular
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FIGURE 1 | Amino acid sequences of UII and URP in mammalian species; <Gln, pyroglumatic acid. Modified from Vaudry et al. (2010).
FIGURE 2 | Central and peripheral distribution of prepro-UII, prepro-URP, and UT in (A) primates (human and cynomolgus monkey) and (B) rodents
(rat and mouse) (Ames et al., 1999; Sugo et al., 2003; Dubessy et al., 2008; Maguire et al., 2008; Doan et al., 2012; Nguyen et al., 2012).
loops (Douglas et al., 2000), this protein also possesses a palmi-
toylation site located in the C-terminal segment of the rodent iso-
form that is not present in the human isoform (Figure 3). Worth
to mention, the rat UT, consisting of 386 amino acids, shows
only 75% homology with the human protein while sequences
of human and monkey receptors, comprising 389 residues, are
almost identical (Elshourbagy et al., 2002). Like UII and URP,
UT is widely expressed in the central nervous system as well as
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FIGURE 3 | Schematic representation of the human urotensin II (hUT) receptor. Adapted from Douglas et al. (2000).
in various peripheral organs including the cardiovascular system,
kidneys, bladder, pancreas, and adrenal gland (Figure 2) (Vaudry
et al., 2010).
The urotensinergic system plays a seminal role in the physio-
logical regulation of major mammalian organ systems, including
the cardiovascular system (Vaudry et al., 2010). As a matter
of fact, UII exerts potent haemodynamic effects (Krum and
Kemp, 2007), positive inotropic and chronotropic responses
(Watson et al., 2003), and osmoregulatory actions (Song et al.,
2006), induces collagen and fibronectin accumulation (Dai et al.,
2007; Zhang et al., 2008), modulates the inflammatory response
(Shiraishi et al., 2008), plays a role in the induction of cardiac
and vascular hypertrophy (Papadopoulos et al., 2008), causes a
strong angiogenic effect (Guidolin et al., 2010) and inhibits the
glucose-induced insulin release (Silvestre et al., 2004). Thus, the
urotensinergic system was linked to numerous pathophysiolog-
ical states including atherosclerosis, heart failure, hypertension,
pre-eclampsia, diabetes, renal and liver diseases, variceal bleeding,
ulcers, as well as psychological, and neurological disorders (Ross
et al., 2010).
The present review focuses on the latest findings about the
urotensinergic system in terms of receptor localization and phar-
macology as well as receptor activation with the conception of
new urotensinergic ligands aimed at discriminating UII- and/or
URP-mediated biological actions.
DISCOVERY OF AN INTRACRINE PHARMACOLOGY OF THE
UROTENSINERGIC SYSTEM
PRESENCE OF NUCLEAR UT IN THE HEART AND IN THE CENTRAL
NERVOUS SYSTEM
In many ways, UII exhibits actions similar to other key neuro-
hormonal factors, i.e. angiotensin II (Ang-II) and endothelin-1
(ET-1), in driving a variety of cardiac and vascular disease pro-
cesses (Maguire and Davenport, 2002). These include vasocon-
striction as well as mitogenic, trophic and pro-fibrotic effects
(Vaudry et al., 2010). A clear interaction of the urotensinergic
system with the renin-angiotensin-aldosterone and endothelin
systems is acknowledged in terms of regulation of systolic and
diastolic functions (Fontes-Sousa et al., 2009). However, key dif-
ferences were observed between these systems. In particular, UII
induces a rather weak or absent vasoconstriction in a variety of
human vascular beds (Maguire et al., 2000; Hillier et al., 2001)
while it can also acts as a vasodilator in some vascular beds,
such as those in the pulmonary vasculature (Stirrat et al., 2001).
The recent discovery of specific intracellular receptors associated
with the physiological and pathophysiological actions of Ang-
II and ET-1 highlighted a high level of complexity for these
peptidergic systems in the regulation of cardiovascular homeosta-
sis. Traditionally, GPCRs are located at the plasma membrane
where they modulate the activity of membrane-associated sec-
ond messengers. As such, GPCRs can exert their effects through
the regulation of ion channels, second messenger production,
and protein kinase cascades in order to control cellular activ-
ity, gene expression, plasticity, differentiation, morphogenesis,
and migration. However, in the recent years, the presence of
functional intracellular receptors has almost become “a clas-
sic GPCR paradigm” (Boivin et al., 2008). These intracellular
GPCRs could be involved in the control of several cellular pro-
cesses including regulation of gene transcription, ionic homeosta-
sis, cellular proliferation, and remodeling (Boivin et al., 2008).
Intracellular GPCRs may be constitutively active, or may be acti-
vated by ligands internalized from the extracellular space or
synthesized within the cell (Figure 4). Besides, they can reg-
ulate signaling pathways distinct from those activated by the
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FIGURE 4 | Proposed trafficking of UT and endogenous ligands. UT
receptors are located either at the plasma membrane or at the nucleus. The
presence of nuclear UTs can be attributed to lateral diffusion of newly
synthesized proteins from the rough endoplasmic reticulum surface, which is
contiguous with the nuclear shell, to specific nuclear addressing following
modification in the Golgi apparatus or importin-assisted nuclear translocation
after ligand stimulation. UII or URP binds to UT receptors at the cell surface
but can also cross the plasma membrane to stimulate intracellular receptors.
From Lee et al. (2004); Giebing et al. (2005); Gobeil et al. (2006); Doan et al.
(2012); Tadevosyan et al. (2012).
same receptor at the cell surface (Re, 1999). As such, biologi-
cal outcomes might result from the integration of extracellular
and intracellular signaling events (Terrillon and Bouvier, 2004;
Hanyaloglu and von Zastrow, 2008; Sorkin and von Zastrow,
2009). This new paradigm for cellular signaling provides more
complexity to study the function and physiological roles of
GPCRs.
In a recent report, specific UII binding sites were observed on
heart and brain cell nuclei from rat and monkey tissues (Doan
et al., 2012; Nguyen et al., 2012). Except those two tissues and
the spinal cord, none of the tested tissues including kidneys, lung,
and skeletal muscle, all expressing UT at the cell surface, pre-
sented a subcellular localization of UT (Doan et al., 2012; Nguyen
et al., 2012). Supporting the presence of such nuclear expression
also in humans, the presence of nuclear UT was also observed
in two human cell lines, i.e. SH-SY5Y neuroblastoma and U87
astrocytoma cell lines (Nguyen et al., 2012).
NUCLEAR UT ACTIVATION CANMODULATE TRANSCRIPTION
INITIATION
As previously reported for nuclear Ang-II (Eggena et al., 1993),
β3-adrenergic (Boivin et al., 2006; Vaniotis et al., 2011), and
ET-1 receptors (Boivin et al., 2003), nuclear UT receptors can
initiate transcription (Doan et al., 2012; Nguyen et al., 2012).
Although UII and URP stimulated the transcription in isolated
brain cell nuclei (Nguyen et al., 2012), only UII was able to
trigger a similar effect in rat cardiac nuclei (Doan et al., 2012).
Two-dimensional gel electrophoresis clearly indicated the occur-
rence of different immunoreactive species in both brain and heart
membrane and nuclear fractions (Doan et al., 2012; Nguyen et al.,
2012). Nuclear and membrane proteins extracted from heart tis-
sues expressed three major UT-immunoreactive spots with an
apparent molecular weight of 60 kDa at a pI value of 6–7 (Doan
et al., 2012). Interestingly, a different pattern was observed in
brain tissue (Nguyen et al., 2012). Since the UT gene is intronless,
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the various immunoreactive species were principally ascribed to
post-translational modifications (Doan et al., 2012; Nguyen et al.,
2012). Whether or not these UT species are involved in distinct
UII-associated biological activities will require further investiga-
tion. However, it is well-known that glycosylation can modulate
the cellular compartmentalization and functionality of the recep-
tor, thereby influencing its intracellular trafficking and biological
activity (Figure 4) (Duverger et al., 1995; Rondanino et al., 2003;
Gobeil et al., 2006).
A growing body of evidence supports the presence of GPCRs at
the surface of the nuclear membrane, their orientation within this
membrane, however, remains controversial. If they maintain the
topology adopted in the endoplasmic reticulum during protein
synthesis, the ligand binding site would be located in the lumen
of the nuclear envelop (perinuclear space) with the C-terminal of
the protein being localized either within or outside the nucleus. In
fact, the topology of the nuclear membrane lumen is very similar
to the extracellular space, which makes it a favorable environ-
ment for a binding site (Jong et al., 2005; Bootman et al., 2009).
Since signaling starts with the recruitment of specific proteins
to the C-terminal portion of the receptor, signals would be sent
toward the cytosol or into the nucleus in accordance with the
adopted GPCR orientation within the nuclear shell (Figure 5).
Hence, the orientation of those nuclear GPCRs would deter-
mine the direction in which the signal is transmitted. As recently
reported, nuclear UT receptors are able to regulate gene tran-
scription (Doan et al., 2012; Nguyen et al., 2012). Furthermore,
it is well-known that calcium ions play an important role in the
control of gene expression (Bootman et al., 2009). In isolated
nuclei, nuclear calcium levels can regulate gene transcription by
interacting with the cyclic AMP response element-binding pro-
tein (CREB) and the downstream regulatory element antagonist
modulator (DREAM), which are constitutively present in the
nucleus. Changes in nucleoplasmic calcium can be achieved by
triggering inositol(1,4,5)-triphosphate receptors (IP3Rs) located
on the inner nuclear membrane (Bootman et al., 2009). Because
it is generally accepted that UT activation is associated with the
recruitment of Gαq/11 proteins to its C-terminal tail resulting in
an IP3 increase (Proulx et al., 2008), it is highly probable that this
portion of the receptor is located into the nucleoplasm (Figure 5).
Interestingly, IP3Rs are concentrated in the nuclear membrane
of heart ventricular cells and their activation was shown to ini-
tiate a pro-hypertrophic pathway (Arantes et al., 2012). These
findings are well-correlated with the UII-induced cardiomyocyte
hypertrophy and the presence of nuclear UT receptors in cardiac
tissues (Gruson et al., 2010; Doan et al., 2012). Nevertheless, these
intracellular UT receptors may have the capacity to regulate sig-
naling pathways that differ from those of their plasma membrane
counterparts, as recently demonstrated for the metabotropic glu-
tamate receptor 5 (Jong et al., 2009), and the renin–angiotensin
system (De Mello, 2008). As such, this intracrine pharmacology
of the urotensinergic system represents a complementary sys-
tem that could potentially involve the regulation of physiological
functions.
INTRACELLULAR TRAFFICKING OF UT
This new intracrine pharmacology clearly highlights the
complexity of this peptidergic system where UII and URP can
trigger not only common but also different biological activities
(Prosser et al., 2008; Jarry et al., 2010; Doan et al., 2012).
Previous studies have detected the presence of GPCRs, such
as Ang-II receptors, at the nucleus in an agonist-independent
manner (Lee et al., 2004). Confocal microscopy of heart and
brain tissue sections as well as various non-transfected cell lines
clearly revealed a constitutive nuclear localization for UT (Doan
et al., 2012; Nguyen et al., 2012). However, it is also possible
that following their agonist-stimulated internalization, GPCRs
relocate at the nuclear membrane (Lee et al., 2004). In such a
case, the translocation is initiated by the presence of a nuclear
localization signal (NLS), a short stretch of basic amino acid
residues often localized within the intracellular loops that is
recognized by importins α and/or β (Figure 4). For example, a
NLS was observed in the seventh transmembrane domain and
the carboxy-terminal segment of the Ang-II receptor subtype1
(Lys-Lys-Phe-Lys-Arg) and the third intracellular loop of the
apelin receptors (Arg-Lys-Arg-Arg-Arg) (Lee et al., 2004).
Interestingly, a similar sequence, i.e. Lys-Arg-Ala-Arg-Arg, is also
observed in the third intracellular loop of human and monkey
UT isoforms (Figure 3) while a Lys-Gln-Thr-Arg-Arg segment is
observed in rat and mouse UT. However, it is important to note
that many NLS signals are still unknown and that the presence of
an obvious NLS motif may mask the existence of still uncharac-
terized NLS sequences. Specific post-translational modifications
such as palmitoylation were reported to be involved in the
addressing of the receptor either to the membrane or the nuclei.
For instance, it was demonstrated that de-palmitoylation of
GRK6A promoted its translocation from the plasma membrane
to both the cytoplasm and nucleus (Jiang et al., 2007). Such
a putative palmitoylation site is also found within the seventh
transmembrane domain (Cys339) of rat and mouse UT isoforms
but is absent in the primate (human and monkey) receptor
(Marchese et al., 1995; Tal et al., 1995; Ames et al., 1999). Under
chemically mediated hypoxic conditions, an increase of total UT
expression, was observed suggesting that hypoxia might induce
de novo synthesis of the peptide receptor. However, a significant
decrease in nuclear UT expression was reported that could be
interpreted as an increase in translocation of the protein to the
membrane or a decrease of internalization with concomitant
nuclear translocation (Nguyen et al., 2012). Altogether, it could
be noted that the subcellular UT localization could be either
attributed to translocation from the cell surface and/or de novo
synthesis (Figure 4).
UII AND URP AS INTRACRINE LIGANDS
UII, and by extension URP, were originally thought to act as
autocrine and paracrine modulators rather than as hormones
(Yoshimoto et al., 2004). The term “intracrine” ligand relates
to intracellular molecules binding to and activating intracellular
receptors (Figure 4). Such ligands can be synthesized and targeted
to the Golgi apparatus for secretion or act intracellularly either
before secretion or following reuptake. The intracrine gene prod-
uct might also arise from an alternative transcription initiation
site, differences in mRNA maturation or translation leading to
a gene product lacking secretory signals and consequently active
only in the intracellular space (Figure 4) (Kiefer et al., 1994; Lee-
Kirsch et al., 1999; Xu et al., 2009). To this extent, it is interesting
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FIGURE 5 | Proposed UT-associated signaling pathways. Activated
UTs are known to recruit Gαq/11 proteins and to signal through
different pathways associated with an elevation of intracellular
calcium and gene transcription. Nuclear UTs could induce transcription
through a pathway involving the production of IP3 that would trigger
IP3Rs at the inner nuclear envelop, releasing calcium in the
nucleoplasm. This latter event is crucial to initiate transcription through
transcription factors such as CREB and DREAM. From Proulx et al.
(2008); Bootman et al. (2009); Vaudry et al. (2010); Roskoski (2012);
Tadevosyan et al. (2012).
to note that two isoforms of the human UII precursor, differing
mostly by their peptide signal, were discovered (Coulouarn et al.,
1998; Ames et al., 1999).
A recent study demonstrated that FITC-conjugated hUII and
URP were both internalized in non-expressing UT cell lines
through receptor-independent mediated endocytosis (Doan et al.,
2012) (Figure 4). This receptor-independent endocytic mecha-
nism brought a new perception of the pseudo-irreversible bind-
ing characteristics often described for the urotensinergic system.
Indeed, the lack of rapid UT desensitization through classic
mechanisms (acid wash or trypsin treatments) was thought
to reflect a strong, pseudo-irreversible binding of the ligands
(Douglas and Ohlstein, 2000). However, this pseudo-irreversible
character could also be due to the ability of both endogenous pep-
tides to reach the internal compartment of the cell. Moreover, it is
yet possible that following the internalization of ligand-receptor
complexes, ligands are subsequently released from internalized
endosomes within the cell. As such, internalized peptide-receptor
complexes can be dissociated under the acidic environment found
in endosomes, giving rise to receptor recycling at the plasma
membrane (Figure 4) (Giebing et al., 2005). At this point, the
fate of the peptide is unknown but based on the results published
by Doan et al. (2012), it is conceivable that UII, and to a lesser
extend URP, could leak from the vesicle and ultimately activate
intracellular receptors.
PROSPECTIVE ROLES OF NUCLEAR UT
The precise role of this new intracrine urotensinergic system has
yet to be elucidated both in physiological and pathological con-
ditions. However, as for other GPCRs including Ang-II and ET-1
receptors, these intracellular receptors are important regulators
of physiological and pathological functions and could therefore
represent new targets for therapeutic interventions (Boivin et al.,
2008; Tadevosyan et al., 2012).
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Elevated UII plasma levels were observed in numerous disease
conditions, including hypertension, atherosclerosis, heart failure,
pulmonary hypertension, diabetes, renal failure, and metabolic
syndrome (Ross et al., 2010). As demonstrated, the cellular uptake
of UII but not URP is increased at lower pH (Doan et al., 2012).
Pathological conditions such as cancer, ischemic stroke, inflam-
mation, and atherosclerotic plaques often induce an increase in
metabolic activity and hypoxia associated with an elevated extra-
cellular acidity (Andreev et al., 2010). In these conditions, UII
would enter more easily than URP inside the cell triggering
transcription of UII-associated genes by activating the nuclear
receptor. Thus, the elevated concentration of UII observed dur-
ing the etiology of various diseases could sustain specific cellular
responses while an intracellular feedback loop could maintain
a particular cellular state (Petersen et al., 2006). Interestingly,
known intracrines do not present any structural or chemical
similarities but are generally growth regulators that can directly
or indirectly modulate angiogenic or anti-angiogenic actions.
Therefore, the angiogenic actions of the urotensinergic system,
reported both in vivo and in vitro (Spinazzi et al., 2006), could
thus involve the activation of nuclear UT.
The urotensinergic system is also highly expressed in the cen-
tral nervous system, but its physiological function is still poorly
understood. UT was observed in cortical astrocytes (Castel et al.,
2006), a ubiquitous type of glial cell that greatly outnumbers neu-
rons and occupies 25% to 50% of brain volume (Bignami et al.,
1991). It is noteworthy that glioblastoma multiform (GBM) is
characterized by exuberant angiogenesis, a key event in tumor
growth and progression and that UII, URP, and UT mRNAs
were systematically found to be expressed in different glioma and
glioblastoma tumors (Diallo et al., 2007). These results support a
role for the urotensinergic system, and in particular nuclear UT,
in human brain tumorogenesis possibly via angiogenesis regula-
tion. Finally, in the CNS, UII is able to induce norepinephrine,
dopamine, and serotonin release in noradrenergic neurons (Ono
et al., 2008). Intracerebroventricular UII administration modu-
lates cardiac homeostasis via β-adrenoreceptor activation (Hood
et al., 2005). These observations bring up the idea that the pres-
ence of nuclear UT receptors could also be associated to excitatory
neurotransmission. In accordance with this hypothesis, various
intracrines were reported to act as neurotransmitters within the
CNS (Re, 2004).
Whether specific UII or URP biological actions on the CNS
and the cardiovascular system are mediated totally or in part by
the nuclear UT will need further studies as well as the devel-
opment of specific nuclear UT probes. Although still poorly
understood, the diverse functions exerted by agonists and hor-
mones acting on intracellular GPCRs suggest that intracrine
signaling might activate cellular responses distinct from those at
the cell surface for a given receptor. In the last decade, biological
actions of intracrines in heart and vasculature, including those
of the renin–angiotensin-system in cardiac pathology, dynorphin
B in cardiac development, as well as endothelin, highlighted the
importance of intracrine physiology in pathological processes
such as left ventricular hypertrophy, diabetic cardiomyopathy,
and arrythmogenesis. So, the presence of functional UT receptors
at the cell membrane and at the nucleus will probably be a new
aspect to take into account during the development of therapeu-
tic compounds for the treatment of pathologies associated with
the urotensinergic system.
NEW INSIGHTS INTO UT ACTIVATION
The precise definition of the (patho) physiological roles of the
urotensinergic system in vivo was hampered by the absence of
potent and selective UT antagonists. Indeed, the lack of effi-
cacy observed with Palosuran (ACT-058362) (Clozel et al., 2004,
2006), the only UT antagonist that reached a phase II clini-
cal trial in patients with diabetic nephropathy, was clouded by
its low antagonist potency (Behm et al., 2008). Therefore, drug
discovery programs continued to focus on the identification of
potent and selective UT antagonists suitable for assessment in
both preclinical species and man (Maryanoff and Kinney, 2010).
As reported earlier this year, Sanofi launched a phase I clinical trial
regarding a long acting UT antagonist, derived from a 5,6-bisaryl-
2-pyridine-carboxamide scaffold (European patent application
EP2439193), for the treatment of diabetic nephropathy. Similarly,
GlaxoSmithKline started a phase I clinical trial for the use of
an UT antagonist, i.e. SB1440115 (United States Patent applica-
tion 12,373,901), for the treatment of asthma. Finally, over the
past few years, Boehringer-Ingelheim (European patent applica-
tion EP2155748) as well as Janssen Pharmaceutical (United States
Patent application 8,193,191) filled several patents regarding UT
antagonists but no phase I clinical trial was yet reported. With the
recent discovery that UII and URP could exert common as well
as different biological activities (Prosser et al., 2008; Hirose et al.,
2009; Jarry et al., 2010), development of selective UT antagonists
has become a more complex task.
UT AS SHAPESHIFTING PROTEINS
GPCRs represent the largest and most diverse family of cell
surface receptors. These plasma membrane proteins bind their
endogenous ligands in order to activate an intracellular signal-
ing cascade that will result in a biological action. Conventional
views of ligand-receptor activation considered all components of
the signaling cascade to be linearly related, i.e. to emanate from
the initial activation of the receptor. However, multiple stud-
ies pointed out the ability of some ligands to selectively trigger
specific signaling pathways, therefore having collateral and not
linear efficacy (Roettger et al., 1997; Kohout et al., 2004). As
such, GPCRs cannot be considered as pharmacological on/off
switches anymore. Their intrinsic nature rather suggests that
dynamic changes in the receptor conformation, resulting from
ligand binding, are a mean of information transfer (Kenakin and
Miller, 2010). Hence, the propensity of GPCRs to assume mul-
tiple conformations make them allosteric proteins that are able
to select specific subsets of secondary messengers depending on
the ligand-induced adopted conformation. As such, various lig-
ands were reported to possess differential functional profiles for a
given receptor, as it was initially described for the CCR7 receptor
(Kohout et al., 2004).
TheURP sequence, strictly conserved throughout species, sup-
ports the concept that specific receptor interactions were main-
tained despite variation in the receptor amino acid sequence
(Elshourbagy et al., 2002). Based on the specific expression of
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FIGURE 6 | Schematic representation of a proposed binding mode for
UII and URP. Following the initial interaction between the N-terminal domain
of UII and its receptor, UT undergoes a conformational change aimed at
welcoming the C-terminal domain of UII, characterized by an intracyclic β-turn,
in a specific binding pocket. However, URP, lacking this N-terminal portion and
characterized by the presence of an intracyclic γ-turn, is also able to bind UT
but in a slightly different manner, probably characterized by the activation of a
different subset of signaling pathways. Modified from Chatenet et al. (2012a).
URP mRNA in several cerebral structures (rostroventrolateral
medulla) and tissues (heart, seminal vesicle), it was suggested
that URP rather than UII would be the biologically active pep-
tide in the UT-associated regulation of autonomic, cardiovascular
and reproductive functions (Dubessy et al., 2008). Moreover,
distinct pathophysiological roles for UII and URP in hyperten-
sion have been suggested (Hirose et al., 2009). Indeed, mRNA
expression of both UII and URP was up-regulated in the atrium
of spontaneously hypertensive rats (SHR) when compared with
age-matched Wistar Kyoto (WKY) rats. However, the specific up-
regulation of URP but not UII mRNA in aorta and kidney of SHR
rats supported the idea that these peptides might act individually
in various biological systems (Hirose et al., 2009). Accordingly, it
was demonstrated that UII and URP were able to exert not only
common but also divergent physiological actions clearly suggest-
ing the propensity of these two endogenous ligands to select a
specific UT conformation (Prosser et al., 2008; Jarry et al., 2010;
Doan et al., 2012). The concept of biased agonism has recently
emerged from various studies, putting forward the notion that
specific ligand-induced conformational changes can lead to par-
ticular signaling (Patel et al., 2010). In isolated ischaemic heart
experiments, UII and URP were both able to reduce myocardial
damages through creatine kinase reduction but only UII was able
to reduce atrial natriuretic peptide (ANP) production (Prosser
et al., 2008). Supporting the idea that UII and URP interact
with UT in a distinct manner, it was recently demonstrated that
URP, an equipotent UII paralog, was able to accelerate the dis-
sociation rate of membrane bound 125I-hUII while hUII had no
noticeable effect on URP dissociation kinetics (Chatenet et al.,
2012a). Altogether, these results suggest that each ligand is able to
select a specific UT conformation that triggers definite biological
activities for each of these two peptides.
The peptide N-terminal region was initially pointed out as
potentially involved in the observed biological activity differences
between UII and URP (Prosser et al., 2008). However, it is only
recently that this region was clearly associated with a putative dif-
ferential binding mode of hUII and URP (Chatenet et al., 2012a).
Using exocyclic Ala-derivatives of hUII, acting as very potent
ligands of the UT receptor (Brkovic et al., 2003), dissociation
kinetics experiments revealed a putative interaction between UT
and the glutamic residue at position 1 of hUII. Indeed, it was
observed that the replacement of this residue by an alanine moi-
ety, i.e. [Ala1]hUII, provoked an increase of the dissociation rate
of hUII but not URP (Chatenet et al., 2012a). In agreement with
this view, an important electrostatic interaction between Glu1 of
hUII and its receptor was previously reported in docking studies
(Lescot et al., 2008). No other substitution was able to induce such
pharmacological changes. Because this compound was reported
to exert almost equipotent contractile activity compared to hUII
and URP, the lost of a putative specific interaction with UT was
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thought to have generated an analog behaving as an URP deriva-
tive therefore acting at the URP-associated orthosteric binding
site. Supporting this hypothesis, hUII(4–11), considered as the
minimal hUII fragment to exert full biological activity, was also
able to alter hUII but not URP dissociation rate (Chatenet et al.,
2012a). This N-terminal segment could thus be crucial for sig-
naling pathway selection upon activation and its deletion could
lead to signaling mechanism misinterpretation, all UII truncated
analogs potentially acting as URP derivatives.
Overall, these results support the presence of specific pock-
ets/interactions within UT, aimed at selecting distinct UT confor-
mations that can differentiate UII and URP biological activities
(Figure 6). Briefly, it is hypothesized that upon the initial UII-UT
interaction, involving the N-terminal region of UII, UT under-
goes conformational changes aimed at welcoming the C-terminal
domain of UII, characterized by an intracyclic β-turn (Carotenuto
et al., 2004). To the opposite, URP, lacking this N-terminal por-
tion and characterized by the presence of an intracyclic γ-turn
(Chatenet et al., 2004), would bind UT in a slightly different
manner; ultimately triggering a slightly different subset of sig-
naling pathways. These observations have clearly highlighted the
crucial need to reassess the development of pan UT antagonists,
i.e. blocking UII- and URP-mediated receptor activation, and
to develop new analogs of the urotensinergic system aimed at
discriminating UII- or URP-mediated biological activities. Such
compounds would allow a better understanding of the patho-
physiological roles of the urotensinergic system and also expand
our knowledge on allosteric modulation of class A GPCRs.
Allosteric modulation of the urotensinergic system
As demonstrated, the urotensinergic system is far more complex
than previously thought with the presence of nuclear receptors
and UII/URP specific as well as common actions. For the past two
decades, identification of peptidic and non-peptidic agonists and
antagonists of the urotensinergic system has gathered much inter-
est for the treatment of various cardiovascular pathologies. An
extensive review regarding the various peptidic and non-peptidic
ligands of the urotensinergic system, all acting as competitive
compounds, is beyond the scope of this review but more details
can be found elsewhere (Maryanoff and Kinney, 2010).
Additional biological complexity, but also novel opportunities
for drug discovery, has arisen from the fact that many GPCRs pos-
sess allosteric binding sites (Christopoulos and Kenakin, 2002).
Similar to the initial concept of agonism, i.e. linear efficacy, antag-
onism has been historically viewed as a simple “turning off” of
the receptor. As such, this non-accommodating mechanism does
not allow any agonist to impart information to the receptor, the
orthosteric binding site being occupied by the competitive antag-
onist. However, an allosteric modulator binds to its own site,
different from the orthosteric site, forming a complex charac-
terized by the concomitant presence of the endogenous agonist
and the allosteric modulator. Such modulators can alter the bio-
logical properties of the endogenous orthosteric ligand either via
changing its affinity, its efficacy, or both (Leach et al., 2007; May
et al., 2007). This type of antagonism, termed permissive, can
modify the reactivity of the receptor toward the agonist proba-
bly through conformation selection and stabilization of one or
FIGURE 7 | Structure of the novel UT allosteric modulators of the
urotensinergic system, i.e. [Bip4]URP (urocontrin), [Pep4]URP
(urocontrin A; UCA), and rUII(1–7). Modified from Chatenet et al.
(2012a,b).
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part of the receptor states. Targeting receptor allosteric sites can
offer the possibility of greater selectivity due to a lower sequence
conservation within allosteric pockets across subtypes of a given
GPCR, as well as the potential to fine-tune physiological signal-
ing in a more spatial and temporally-selective manner (Kenakin,
2011).
The urotensinergic system, encompassing two endogenous
peptides, provides potential for allosteric compounds to dif-
ferentially modulate individual peptide responses, a behavior
termed “probe dependence” (Kenakin, 2008). During the course
of structure-activity relationship studies on URP derivatives, two
compounds, i.e. [Bip4]URP and [Pep4]URP, termed urocontrin
and urocontrin A (UCA) respectively, showed a specific behavior
that has set them apart from known UT antagonists (Figure 7)
(Chatenet et al., 2012a,b). Indeed, these compounds were able
to selectively and significantly reduce hUII-induced contraction
without altering URP-mediated vasoconstriction (Chatenet et al.,
2012a,b). For instance, the efficacy of hUII-induced rat aortic
ring vasoconstriction was significantly reduced (∼31%) by a pre-
treatment with a nanomolar concentration of UCA (Figure 8).
Interestingly, this ability to selectively and significantly reduce
UII-induced contraction was not specie-dependent since a sim-
ilar effect was observed on cynomolgus monkey aortic rings. To
the best of our knowledge, only two other UT ligands exerted
insurmountable activity (Herold et al., 2003; Behm et al., 2010).
However, none of them could differentially alter hUII and URP
biological activity. The insurmountable nature of urocontrin and
UCA antagonism was attributed to an allosteric modulation of
UT. Indeed, an excess of UCA accelerated the 125I-hUII disso-
ciation rate, thus suggesting that the binding of the antagonist
changes the receptor conformation in such a way that the radioli-
gand is released from the receptor. Accordingly, no difference in
125I-URP dissociation kinetics was observed in similar conditions
(Figure 8). The apparent absence of effect on the URP pharma-
cological profile by UCA was attributed to its ability to select
a receptor conformation through functional allosteric modula-
tion that impairs hUII-associated actions but not URP-mediated
biological activities.
As stated above, for a given receptor, an allosteric modulation
that depends on the type of orthosteric ligand used is referred to
as “probe dependence” (Kenakin, 2005; Keov et al., 2011). This
probe dependence phenomenon supports the idea that the two
endogenous ligands, despite depicting a high structure homology
and recognizing a similar binding pocket, represent chemically
distinct entities interacting in different structural environments
within the orthosteric pocket. Because hUII and URP differ
only by the length and composition of their N-terminal domain
(Vaudry et al., 2010), it was postulated that this region could be
involved in their putative different bindingmodes. Corroborating
this hypothesis, the hUII counterpart of UCA, i.e. [Pep7]hUII,
FIGURE 8 | Schematic representation of a proposed allosteric
modulation of the urotensinergic system by urocontrin A and rUII(1–7).
By acting at an allosteric binding site, UCA is able to modify the receptor
topography preventing the proper interaction of UT with the linear UII
N-terminal region ultimately leading to an inefficient activation characterized
by a reduced efficacy. On the opposite, such a receptor conformational
change has no effect on URP-mediated action. Conversely, binding of the
rUII(1–7) N-terminal segment, initiates a topographical change that
antagonizes the effect of URP, but not UII. Modified from Chatenet et al.
(2012a).
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acted as a weak but full agonist of the UT receptor (Chatenet
et al., 2012a). This N-terminal domain is thus able to mod-
ulate the topology of the receptor in such a manner that the
C-terminal domain of UII is able to trigger receptor activation.
However, could this N-terminal segment be biologically active?
As an agonist, the N-terminal domain of rat UII [rUII(1–7)], i.e.
Pyr-His-Gly-Thr-Ala-Pro-Glu-amide (Figure 7), was unable to
induce the contraction of rat aortic rings (Chatenet et al., 2012a).
Amazingly, pre-treatment of rat aortic rings with rUII(1–7)
induced an apparent increase in rUII contractile efficacy while
reducing the potency and the efficacy of URP-mediated vasocon-
striction (Chatenet et al., 2012a). These results clearly suggested
that rUII(1–7) acted as a probe dependant allosteric modu-
lator on rUII- and URP-mediated vasoconstriction (Figure 8)
(Chatenet et al., 2012a). Since all UII isoforms possess differ-
ent N-terminal domains, it is hypothesized that these regions
could act as specie-selective specific URP modulators but there
is currently no clue regarding an endogenous production of those
N-terminal UII domains in vivo.
CONCLUSIONS
These latest findings about the urotensinergic system will
probably generate a considerable interest within the scientific
community. First, the discovery of UT on the nuclear membrane
and the presence of intracellular ligands open up new avenues in
UT signaling physiology. In general, nuclear-localized receptors
may regulate distinct signaling pathways, suggesting that biolog-
ical responses mediated by GPCRs are not only initiated at the
cell surface but might result from the integration of extracel-
lular and intracellular signaling pathways. These receptors are
therefore well-positioned to play major roles in the physiological
and pathophysiological responses associated with their endoge-
nous ligands. Finally, the discovery of allosteric modulators of the
urotensinergic systems such as urocontrin, UCA, and rUII(1–7),
will surely enable a better understanding of the urotensinergic
system by allowing to discriminate in vitro and in vivo specific
biological actions mediated by UII and/or URP. Therefore, these
unique derivatives will be useful as chemical templates for the
rational design of novel UT receptor ligands, as well as pharma-
cological tools for in vitro and particularly in vivo studies aimed at
clarifying the role(s) played by the UII/URP/UT receptor system
in physiology and pathology.
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